EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00139095" target="_blank" >RIV/00216224:14160/24:00139095 - isvavai.cz</a>
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
Original language description
TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis. TAK-279 is a highly potent, selective, oral, allosteric TYK2 inhibitor shown to be clinically effective with an acceptable safety profile in a phase 2b trial in patients with moderate-to-severe psoriasis.¹ Objectives: To evaluate efficacy and safety of TAK-279 in patients with active PsA treated over 12 weeks.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů